Home » Stocks » ARAV

Aravive, Inc. (ARAV)

Stock Price: $5.79 USD 0.11 (1.94%)
Updated December 2, 4:00 PM EST - Market closed
After-hours: $5.80 +0.01 (0.17%) Dec 2, 7:14 PM

Stock Price Chart

Key Info

Market Cap 93.15M
Revenue (ttm) n/a
Net Income (ttm) -30.83M
Shares Out 16.06M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $5.79
Previous Close $5.68
Change ($) 0.11
Change (%) 1.94%
Day's Open 5.64
Day's Range 5.55 - 5.87
Day's Volume 65,484
52-Week Range 3.50 - 14.81

More Stats

Market Cap 93.15M
Enterprise Value 45.16M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 16.06M
Float n/a
EPS (basic) -2.04
EPS (diluted) -2.07
FCF / Share -1.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 899,364
Short Ratio 8.75
Short % of Float n/a
Beta 3.27
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.84
Revenue n/a
Operating Income -31.90M
Net Income -30.83M
Free Cash Flow -21.47M
Net Cash 47.99M
Net Cash / Share 2.98
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -26.36%
ROE -63.63%
ROIC -230.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$22.75*
(292.92% upside)
Low
15.0
Current: $5.79
High
30.0
Target: 22.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue4.751.3740.00-----
Revenue Growth246.68%-96.57%------
Gross Profit4.751.3740.00-----
Operating Income-21.77-75.41-84.48-96.32-82.51-46.11-19.28-12.90
Net Income-18.22-76.33-84.98-95.82-82.18-57.51-18.50-13.22
Shares Outstanding11.597.175.875.134.833.150.080.02
Earnings Per Share-1.57-10.64-14.47-18.66-17.04-26.34-246.60-688.25
Operating Cash Flow-17.08-29.26-116-40.63-69.06-39.65-17.09-11.72
Capital Expenditures--0.03-4.30-0.09--0.83-0.01-
Free Cash Flow-17.08-29.29-121-40.72-69.06-40.48-17.10-11.72
Cash & Equivalents67.5659.3983.5320118217113.290.40
Total Debt10.23-5.43----4.46
Net Cash / Debt57.3259.3978.1020118217113.29-4.06
Assets82.1269.4793.7820618517414.682.19
Liabilities13.079.5311.0254.508.836.934.487.28
Book Value69.0559.9582.76151177167-47.29-34.74
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aravive, Inc.
Country United States
Employees 16
CEO Gail McIntyre

Stock Information

Ticker Symbol ARAV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARAV
IPO Date March 21, 2014

Description

Aravive, a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.